RPRX

insider transactions

Royalty Pharma plc — buys & sells by directors, officers and 10% owners (SEC Form 4).

30D 90D 1Y

Net shares · 90d

-164.4K

0 buy · 164.4K sell

Net value · 90d

-$8.5M

$0 in · $8.5M out

Sentiment · 90d

Net selling

0% buying · 100% selling

Open-market trades · 90d

0 buy · 164.4K sell

Net buy / sell volume

Tap or hover the chart for daily net volume. Green = net buying, red = net selling.

All transactions

Grant·A
Jun 17, 26

Ted W Love

Director

$0

39.5K sh

Own New
Grant·A
Jun 10, 26

Gregory Norden

Director

$0

648 sh

Own New
Grant·A
Jun 10, 26

Gregory Norden

Director

$0

1.4K sh

Own +729%
Grant·A
Jun 5, 26

Elizabeth H Weatherman

Director

$0

4.5K sh

Own +53%
Grant·A
Jun 5, 26

Gregory Norden

Director

$0

4.5K sh

Own +2%
Grant·A
Jun 5, 26

Ted W Love

Director

$0

4.5K sh

Own +8%
Grant·A
Jun 5, 26

Carole Ho

Director

$0

4.5K sh

Own New
Grant·A
Jun 5, 26

Catherine M. Engelbert

Director

$0

4.5K sh

Own +9%
Grant·A
Jun 5, 26

Vlad Coric

Director

$0

4.5K sh

Own +42%
Grant·A
Jun 5, 26

Bonnie L Bassler

Director

$0

4.5K sh

Own +6%
Grant·A
May 28, 26

Pablo G. Legorreta

Director, 10% Owner

$0

135.0K sh

Own New
Sell·S
May 26, 26

Terrance P. Coyne KEY

EVP & CFO · 10b5-1

$3.5M

64.4K sh · $53.98

Own -100%
Sell·S
May 20, 26

Marshall Urist

EVP, Research & Investments · 10b5-1

$721.8K

13.7K sh · $52.75

Own -43%
Sell·S
May 14, 26

Marshall Urist

EVP, Research & Investments · 10b5-1

$726.1K

13.7K sh · $53.06

Own -30%
Sell·S
May 14, 26

Gregory Norden

Director · 10b5-1

$161.4K

3.0K sh · $53.00

Own -2%
Grant·A
May 6, 26

Marshall Urist

EVP, Research & Investments

$0

18.2K sh

Own +66%
Grant·A
May 6, 26

Pablo G. Legorreta KEY

CEO, Chairman of the Board

$0

143.8K sh

Own +13%
Grant·A
May 6, 26

Christopher Hite KEY

EVP & Vice Chairman

$0

24.3K sh

Own +4%
Grant·A
May 6, 26

Terrance P. Coyne KEY

EVP & CFO

$0

24.3K sh

Own +60%
Sell·S
Apr 28, 26

Terrance P. Coyne KEY

EVP & CFO · 10b5-1

$93.3K

1.9K sh · $49.78

Own -4%
Sell·S
Apr 28, 26

Terrance P. Coyne KEY

EVP & CFO · 10b5-1

$1.6M

32.9K sh · $49.78

Own -100%
Grant·A
Apr 16, 26

Christopher Hite

Director

$0

38.3K sh

Own New
Sell·S
Apr 1, 26

Terrance P. Coyne KEY

EVP & CFO · 10b5-1

$1.6M

32.9K sh · $48.33

Own -50%
Sell·S
Apr 1, 26

Terrance P. Coyne KEY

EVP & CFO · 10b5-1

$90.6K

1.9K sh · $48.33

Own -4%
Grant·A
Mar 31, 26

Bonnie L Bassler

Director

$37.5K

815 sh · $45.98

Own +1%

Date▾	Insider	Role	Type	Shares	Own Δ	Price	Value
Jun 17, 2026	Ted W Love	Director	Grant A	39.5K	New	—	$0
Jun 10, 2026	Gregory Norden	Director	Grant A	648	New	—	$0
Jun 10, 2026	Gregory Norden	Director	Grant A	1.4K	+729%	—	$0
Jun 5, 2026	Elizabeth H Weatherman	Director	Grant A	4.5K	+53%	—	$0
Jun 5, 2026	Gregory Norden	Director	Grant A	4.5K	+2%	—	$0
Jun 5, 2026	Ted W Love	Director	Grant A	4.5K	+8%	—	$0
Jun 5, 2026	Carole Ho	Director	Grant A	4.5K	New	—	$0
Jun 5, 2026	Catherine M. Engelbert	Director	Grant A	4.5K	+9%	—	$0
Jun 5, 2026	Vlad Coric	Director	Grant A	4.5K	+42%	—	$0
Jun 5, 2026	Bonnie L Bassler	Director	Grant A	4.5K	+6%	—	$0
May 28, 2026	Pablo G. Legorreta	Director, 10% Owner	Grant A	135.0K	New	—	$0
May 26, 2026	Terrance P. Coyne KEY 10b5-1	EVP & CFO	Sell S	64.4K	-100%	$53.98	$3.5M
May 20, 2026	Marshall Urist 10b5-1	EVP, Research & Investments	Sell S	13.7K	-43%	$52.75	$721.8K
May 14, 2026	Marshall Urist 10b5-1	EVP, Research & Investments	Sell S	13.7K	-30%	$53.06	$726.1K
May 14, 2026	Gregory Norden 10b5-1	Director	Sell S	3.0K	-2%	$53.00	$161.4K
May 6, 2026	Marshall Urist	EVP, Research & Investments	Grant A	18.2K	+66%	—	$0
May 6, 2026	Pablo G. Legorreta KEY	CEO, Chairman of the Board	Grant A	143.8K	+13%	—	$0
May 6, 2026	Christopher Hite KEY	EVP & Vice Chairman	Grant A	24.3K	+4%	—	$0
May 6, 2026	Terrance P. Coyne KEY	EVP & CFO	Grant A	24.3K	+60%	—	$0
Apr 28, 2026	Terrance P. Coyne KEY 10b5-1	EVP & CFO	Sell S	1.9K	-4%	$49.78	$93.3K
Apr 28, 2026	Terrance P. Coyne KEY 10b5-1	EVP & CFO	Sell S	32.9K	-100%	$49.78	$1.6M
Apr 16, 2026	Christopher Hite	Director	Grant A	38.3K	New	—	$0
Apr 1, 2026	Terrance P. Coyne KEY 10b5-1	EVP & CFO	Sell S	32.9K	-50%	$48.33	$1.6M
Apr 1, 2026	Terrance P. Coyne KEY 10b5-1	EVP & CFO	Sell S	1.9K	-4%	$48.33	$90.6K
Mar 31, 2026	Bonnie L Bassler	Director	Grant A	815	+1%	$45.98	$37.5K

About RPRX insider trading

This page tracks insider transactions for Royalty Pharma plc (RPRX) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.